MedPath

TTO Swabs Versus Baby Shampoo in Patients With Seborrehic Blepharitis

Phase 4
Completed
Conditions
Seborrheic Blepharitis
Interventions
Drug: Swabs containing tea tree oil and chamomile oil
Drug: Baby shampoo
Registration Number
NCT04678531
Lead Sponsor
Istanbul University - Cerrahpasa (IUC)
Brief Summary

The aim of the study was to compare the efficacy of lid swabs containing tea tree oil (TTO) and chamomile oil and baby shampoo (BS) in the treatment of seborrheic blepharitis.

Detailed Description

After being informed about the study and potential risks, all patients giving written consent will have a complete ophthalmological examination to determine eligibilty for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a double blind manner (participant and investigator) in a 1:1 ratio using block randomization to lid wipes containing tea tree oil (TTO) and chamomile oil or baby shampoo (twice daily).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
49
Inclusion Criteria
  • Diagnosis of seborrheic blepharitis
Exclusion Criteria
  • Patients with ophthalmological pathologies that may affect the tear film functions including ocular rosacea, contact lens use, history of any ocular surgery, or patients with systemic pathologies or those using systemic medications that may affect the tear film functions
  • Patients younger than 18-year-old
  • Patients who used any treatment for blepharitis within the 6 months prior to the examination

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Swabs containing tea tree oil and chamomile oilSwabs containing tea tree oil and chamomile oilThe swabs will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks.
Baby shampooBaby shampooBaby shampoo will be applied on the eyelids twice a day for 8 weeks followed by a discontinuation period of 4 weeks
Primary Outcome Measures
NameTimeMethod
Efficacy of the treatment assessed by the change in Blepharitis Symptom measure (BLISS) scoreChange from Baseline at 12 weeks

BLISS score is calculated according to the answers given to the questionnaire. Higher BLISS scores is related to a worse outcome. (Range is between 0 and 39)

Secondary Outcome Measures
NameTimeMethod
Efficacy of the treatment assessed by the change in the Schirmer's test results0-4-8-12 weeks

Dry eye evaluation will be made with Schirmer's test.

Efficacy of the treatment assessed by the change in the tear breakup time0-4-8-12 weeks

Dry eye evaluation will be made with tear breakup time.

Efficacy of the treatment assessed by the change in Demodex mite count by light microscopy0-4-8-12 weeks

The number of mites in the epilated 4 eyelashes will be counted under microscope.

Efficacy of the treatment assessed by the change in the ocular surface disease index score0-4-8-12 weeks

OSDI scores are calculated according to the responses to the questionnaire. Higher values are related to a worse outcome (range is between 0-100).

Efficacy of the treatment assessed by the change in the meibomian gland loss0-4-8-12 weeks

Meibomian gland loss will be evaluated using anterior segment analysis system.

Efficacy of the treatment assessed by the change in the non-invasive tear breakup time0-4-8-12 weeks

Dry eye evaluation will be made with non-invasive tear breakup time.

Trial Locations

Locations (1)

Istanbul University-Cerrahpasa

🇹🇷

Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath